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Abstract  High  levels  of  circulating  EBV  load  are  used  as  a  marker  of  post-transplant  lympho-
proliferative  disorders  (PTLD).  There  is  no  consensus  regarding  the  threshold  level  indicative  of
an increase  in  peripheral  EBV  DNA.  The  aim  of  the  study  was  to  clinically  validate  a  developed
EBV quantiﬁcation  assay  for  early  PTLD  detection.
Transversal  study:  paired  peripheral  blood  mononuclear  cells  (PBMC),  plasma  and  oropharyn-
geal lymphoid  tissue  (OLT)  from  children  undergoing  a  solid  organ  transplant  with  (n  =  58)  and
without (n  =  47)  PTLD.  Retrospective  follow-up:  71  paired  PBMC  and  plasma  from  recipients  with
(n =  6)  and  without  (n  =  6)  PTLD  history.  EBV  load  was  determined  by  real-time  PCR.  The  diag-
nostic ability  to  detect  all  PTLD  (categories  1--4),  advanced  PTLD  (categories  2--4)  or  neoplastic
PTLD (categories  3  and  4)  was  estimated  by  analyzing  the  test  performance  at  different  cut-off
values or  with  a  load  variation  greater  than  0.5  log  units.
The higher  diagnostic  performance  for  identifying  all,  advanced  or  neoplastic  PTLD,  was
achieved  with  cut-off  values  of  1.08;  1.60  and  2.47  log  EBV  gEq/105 PBMC  or  2.30;  2.60;
4.47 log  gEq/105 OLT  cells,  respectively.  EBV  DNA  detection  in  plasma  showed  high  speciﬁcity
but low  (all  categories)  or  high  (advanced/neoplastic  categories)  sensitivity  for  PTLD  identiﬁ-
cation. Diagnostic  performance  was  greater  when:  (1)  a  load  variation  in  PBMC  or  plasma  was
identiﬁed;  (2)  combining  the  measure  of  EBV  load  in  PBMC  and  plasma.
The best  diagnostic  ability  to  identify  early  PTLD  stages  was  achieved  by  monitoring  EBV  load
in PBMC  and  plasma  simultaneously;  an  algorithm  was  proposed.a  de  Microbiolog´ıa.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
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Carga  de  virus  Epstein-Barr  en  pacientes  trasplantados:  detección  temprana  de
desórdenes  linfoproliferativos  postrasplante
Resumen  La  carga  alta  del  virus  Epstein-Barr  se  utiliza  como  un  marcador  de  desórdenes  linfo-
proliferativos  postrasplante  (post-transplant  lymphoproliferative  disorders  [PTLD]).  El  objetivo
de este  estudio  fue  validar  clínicamente  un  ensayo  de  cuantiﬁcación  del  virus  Epstein-Barr  para
la detección  temprana  de  PTLD.
Se  efectuó  un  estudio  transversal  en  el  que  se  analizaron  muestras  pareadas  de  células
mononucleares  periféricas  (CMP),  de  plasma  y  de  tejido  linfoide  orofaríngeo  de  nin˜os  con
trasplante  de  órgano  sólido,  con  PTLD  (n  =  58)  y  sin  PTLD  (n  =  47).  En  el  seguimiento  retrospec-
tivo se  incluyeron  71  muestras  pareadas  de  CMP  y  de  plasma  de  trasplantados,  con  PTLD  (n  =  6)
y sin  PTLD  (n  =  6).  La  carga  viral  se  determinó  por  PCR  en  tiempo  real.  Se  estimó  la  capacidad
diagnóstica  para  detectar  PTLD  (categorías:  todas  vs.  avanzadas  vs.  neoplásicas)  analizando
diferentes valores  de  corte  o  una  variación  de  carga  mayor  de  0,5  logaritmos.
El mayor  desempen˜o  diagnóstico  para  identiﬁcar  todos  los  PTLD,  los  avanzados  y  los  neoplási-
cos, se  obtuvo  con  valores  de  corte  de  1,08;  1,60  y  2,47  log  copias/105 en  CMP  y  de  2,30;  2,60
y 4,48  log  copias/105 en  células  de  tejido  linfoide  orofaríngeo,  respectivamente.  La  detección
del ADN  del  virus  Epstein-Barr  en  el  plasma  mostró  una  especiﬁcidad  alta,  pero  una  sensibilidad
baja (todas  las  categorías)  o  alta  (categorías  avanzadas  o  neoplásicas)  para  identiﬁcar  PTLD.  Se
observó el  desempen˜o  diagnóstico  más  alto  en  las  siguientes  condiciones:  1)  al  identiﬁcar  una
variación  de  carga  en  CMP  o  en  plasma;  2)  combinando  la  medición  de  la  carga  viral  en  CMP  y
en plasma.
La mejor  capacidad  diagnóstica  para  identiﬁcar  las  etapas  tempranas  de  los  PTLD  se  logró
mediante  el  seguimiento  simultáneo  de  la  carga  viral  en  CMP  y  en  plasma;  se  propone  un
algoritmo.
© 2016  Asociacio´n  Argentina  de  Microbiolog´ıa.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este  es  un
art´ıculo Open  Access  bajo  la  CC  BY-NC-ND  licencia  (http://creativecommons.org/licencias/by-
nc-nd/4.0/).
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The  Epstein--Barr  virus  (EBV)  infection  is  associated  with
the  development  of  post-transplant  lymphoproliferative
disorders  (PTLD)  in  solid-organ  and  stem  cell  transplant
recipients17.
PTLD  encompass  a  wide  range  of  disorders  including
benign  to  malignant  lymphoproliferations22.  Brieﬂy,  cate-
gory  1  includes  early  benign  PTLD;  category  2,  benign  and
neoplastic  PTLD  and  categories  3  and  4,  neoplastic  PTLD.  It
had  been  noted  that  a  therapeutic  intervention,  particularly
during  the  early  PTLD  phases,  could  reverse  lymphoprolifer-
ation  and  prevent  progression  to  the  irreversible  lymphoma
stage3.
The  association  of  PTLD  and  elevated  levels  of  circulating
EBV  were  ﬁrst  described  in  the  nineties18.  Since  then,  dif-
ferent  authors  showed  that  PTLD,  especially  those  occurring
early  after  transplantation,  are  generally  associated  with  an
increase  in  EBV  DNA  in  peripheral  blood  samples.  This  has  led
to  using  the  EBV  load  as  a  risk  marker  for  this  disease7,8,10.
Initially,  many  studies  explored  the  clinical  usefulness  of
these  tests  in  a  single  sample  in  the  presence  of  disease19,20.
Then,  the  importance  of  surveillance  through  frequent
repetitive  monitoring  was  brought  up11.  At  present,  a  high
viral  load  is  used  for  two  purposes:  an  early  diagnosis  (indi-
cating  when  to  start  the  search  for  disease  in  a  potential
site),  and  as  a  prevention  strategy  (indicating  when  to  the-
rapeutically  intervene)6,10.  Furthermore,  some  authors  have
proposed  to  calculate  an  average  load  in  a  set  time,  rather
a
p
ahan  use  a  single  cut-off  value6.  Thus,  a  reduction  in  PTLD
orbidity  and  mortality  was  reported  in  centers  that  had
mplemented  systematic  EBV  load  monitoring,  and  the  viral
urden  was  maintained  at  levels  deﬁned  as  ‘‘low’’,  by  reg-
lating  the  degree  of  immunosuppression12.
In  the  literature,  the  deﬁnition  of  a  threshold  indicative
f  a  ‘‘high  load’’  is  inconsistent  because  each  laboratory
as  implemented  its  own  cut-off  values  to  distinguish  PTLD
rom  baseline  levels13.  The  broad  diversity  of  methods
type  of  quantitative  PCR,  ampliﬁed  viral  fragment),  type
nd  quantity  of  clinical  sample  analyzed  (peripheral  blood
ononuclear  cells,  PBMC;  whole  blood;  plasma),  controls
sed  to  standardize  assays,  expression  of  results  (number  of
iral  genome  equivalents  per  number  of  cells,  DNA  quantity,
olume),  sampling  frequency,  among  others,  have  made  it
ifﬁcult  to  compare  published  data  and  extrapolate  cut-off
alues  from  one  laboratory  to  another.  Therefore,  the  over-
ll  sensitivity,  speciﬁcity,  positive  and  negative  predictive
alues  obtained  by  different  authors  relied  on  the  popula-
ion  studied  (adult  vs.  pediatric),  type  of  transplanted  organ
solid  organ  vs.  stem  cells),  pre-transplant  infection  status,
mong  others.
An  assay  to  quantify  EBV  by  real-time  PCR  was  devel-
ped  in  our  laboratory  to  monitor  transplant  patients5.
hus,  considering  the  lack  of  consensus  on  the  EBV  level
hat  identiﬁes  PTLD,  the  optimal  type  of  clinical  sample,
nd  using  the  logistics  implemented  to  handle  transplant
atients’  samples  in  our  laboratory  (already  underway  using
 semi-quantitative  PCR)4,  the  EBV  load  in  this  report  was
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f12  
nalyzed  in  different  clinical  specimens,  which  also  repre-
ent  anatomical  sites  of  viral  persistence.  Therefore,  the
im  of  this  study  was  to  clinically  validate  the  developed
BV  quantiﬁcation  assay  for  the  early  detection  of  PTLD  in
ransplant  patients.
aterials and methods
atients  and  samples
ediatric  recipients  of  solid  organ  transplants  treated  at
‘Prof.  Dr  Juan  P.  Garrahan’’  Pediatric  Hospital,  Austral
niversity  Hospital,  Sor  María  Ludovica  Children’s  Hospi-
al  and  Favaloro  Foundation  between  2001  and  2010  were
elected  for  inclusion  in  the  present  study.  All  patients  were
ound  to  be  infected  with  EBV,  as  established  by  the  previ-
us  detection  of  IgG  antibodies  against  viral  capsid  antigen
nd/or  EBV-DNA  in  PBMC.  Samples  were  obtained  accord-
ng  to  the  monitoring  of  transplanted  patients  or  treatment
rotocol  and  their  selection  was  based  on  clinical  data  (pres-
nce  or  absence  of  signs  and  symptoms  associated  with
BV  infection),  previous  EBV  load  results  acquired  by  semi-
uantitative  PCR4 (including  varying  EBV  load  levels:  low,
igh  and  very  high)  and  histopathological  examination  of
iopsy  material  (PTLD  or  a  different  diagnosis  based  on  the
orresponding  lymphoid  tissue).
An  informed  consent  was  obtained  from  all  patients  in
ccordance  with  the  Helsinki  declaration  and  other  national
r  international  regulations.  All  procedures  were  approved
y  the  Ethical  Research  Committee,  National  Center  of  Medi-
al  Genetics,  ANLIS  ‘‘Dr.  Carlos  G.  Malbrán’’.
ransversal  study  design
aired  peripheral  blood  and  oropharyngeal  lymphoid  tis-
ue  (OLT)  samples  from  105  pediatric  solid-organ  transplant
ecipients  were  included.  Fifty-eight  of  them  were  histolog-
cally  diagnosed  with  PTLD,  according  to  the  World  Health
rganization  classiﬁcation:  IARC,  200822 (Table  1).
etrospective  follow-up  study  designeventy  one  paired  PBMC  and  plasma  samples  were  included
rom  six  organ  recipients  with  a  histological  diagnosis  of
TLD,  and  six  transplant  patients  with  a  variety  of  clinical
onditions  associated  with  EBV,  but  not  with  PTLD.
T
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Table  1  Description  of  the  transplant  population
Transplanted  organ  Mean  of  the  age  at
transplant  (years)
Non-PTL
LIVER  (n  =  79)  3.0  (0.5--11)  42  
KIDNEY (n  =  24)  8.4  (2--12)  5  
HEART (n  =  2)  9.5  (9--10)  0  
The age of the transplant population ranged between 1 and 18 years (m
a All patients presented a histological diagnosis of follicular lymphoid
b The PTLD cases included: Category 1: 40 lymphoid hyperplasia and 
and polyclonal hyperplasia; Category 3: 4 immunoblastic and 2 BurkittM.D.  Fellner  et  al.
PBMC  and  plasma  were  separated  from  2.5  to  5  ml  of
DTA-anticoagulated  whole  blood  samples  by  centrifugation
n  a  density  gradient  (Histopaque-1077,  Sigma--Aldrich)  as
ecommended,  and  then  stored  at  −20 ◦C.  The  OLT  from
atients  with  lymphoid  hypertrophy  were  surgically  removed
nd  immediately  stored  at  −80 ◦C.
NA  extraction
NA  from  PBMC  and  OLT  samples  was  obtained  as  previously
eported4.
Plasma  DNA  was  extracted  using  the  QIAmp  DNA  mini  kit
QIAgen,  Hilden,  Germany)  following  manufacturers’  recom-
endations  for  free  viral  DNA  extraction.
BV  DNA  quantiﬁcation
e  applied  a  duplex  real-time  PCR  assay  that  simultaneously
mpliﬁes  an  EBNA-1  coding  gene  portion  and  one  of  the
uman  glyceraldehyde  3-phosphate  dehydrogenase  (GAPDH)
ncoding  genes;  the  ampliﬁcation  was  performed  as  previ-
usly  described5.
The  primers/probes  were  as  follows:
EBV  reaction:  5′ CCGCTCCTACCTGCAATATCA  3′ (forward
primer)  and  5′ GGAAACCAGGGAGGCAAATC  3′ (reverse
primer);  5′ VIC-TGCAGCTTTGACGATGG-MGB  3’  (probe).
They  ampliﬁed  a  73  bp  fragment.
GAPDH  reaction:  5′ GGTGGTCTCCTCTGACTTCAACA  3′ (for-
ward  primer);  5′ GTGGTCGTTGAGGGCAATG  3′ (reverse
primer)  and  5′ FAM-CCACTCCTCCACCTTTGACGCTGG-3′
TAMRA  (probe).  They  ampliﬁed  a  79  bp  fragment.
Ampliﬁcation  was  performed  in  a  ﬁnal  reaction  vol-
me  of  25  l,  containing  1×  TaqMan  Universal  Master  Mix
ith  AmpErase  UNG  (Applied  Biosystems,  New  Jersey,  USA),
.3  M  of  EBV-primers,  0.05  M  of  GAPDH-primers,  0.1  M
f  EBV-probe  and  GAPDH-probe  (Applied  Biosystems,  Foster
ity,  USA)  and  the  DNA  to  be  ampliﬁed.
For  each  reaction  around  366  ng  of  DNA  were  assayed
corresponding  to  the  amount  of  DNA  of  105 human  cells4)
rom  PBMC  or  OLT  or  the  extracted  DNA  from  30  l of  plasma.
he  ampliﬁcation  was  performed  using  a  7500  real-time  PCR
ystem  (Applied  Biosystems)  under  the  following  cycle  con-
itions:  50 ◦C  2  min;  95 ◦C  10  min  followed  by  45  cycles  of
5 ◦C  15  s,  60 ◦C  1  min.
Histology  Mean  of  the  time
between  transplant  and
PTLD  diagnosis  (month)Da (n)  PTLDb (n)
37  66  (20--156)
19  54  (6--132)
2  66  (60--72)
ean: 9.0 years) and the male to female rate was 1.1.
 hyperplasia.
2 infectious mononucleosis-like PTLD; Category 2: 8 polymorphic
 lymphomas, and Category 4: 2 Hodgkin lymphomas.
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The  EBV  load  measured  in  PBMC  DNA  was  expressed  as
the  number  of  EBV  genome  equivalents  (gEq)  per  105 PBMC.
The  normalized  EBV  load  was  estimated  from  the  results
of  the  EBNA-1  and  GAPDH  reactions  (EBNA  −  1  load/GAPDH
load  ×  105).  The  EBV  load  in  plasma  was  expressed  as  the
number  of  EBV  gEq  per  ml  of  plasma  by  multiplying  the
EBNA-1  load  by  a  factor  of  33.3  and  correcting  by  extraction
efﬁciency.
Kinetic  variation  was  deﬁned  as  a  greater  than  0.5  log  unit
increase  or  decrease  with  respect  to  the  EBV  load  measured
in  a  previous  sample.  This  implies  a  load  variation  greater
than  the  overall  precision  of  the  method5 and  also  relies  on
the  concept  that  a  difference  higher  than  0.5  log  units  is
clinically  signiﬁcant9.
Clinical  validation
Transversal  study:  it  was  done  in  order  to  analyze  the
diagnostic  performance  of  different  cut-off  values  as  PTLD
indicators.  The  diagnostic  ability  of  the  assay  for  detecting
total  PTLD  (including  categories  1--4),  advanced  PTLD  (cat-
egories  2--4),  or  neoplastic  PTLD  (categories  3  and  4)  cases
(positive  reference  population)  was  evaluated  analyzing  the
sensitivity  and  speciﬁcity  of  different  EBV  load  levels.  The
organ  recipients  without  PTLD  were  considered  the  negative
reference  population.  Paired  PBMC,  plasma  and  OLT  samples
were  analyzed.  The  viral  load  corresponding  to  the  cross-
point  between  sensitivity  and  speciﬁcity  was  considered  the
most  efﬁcient  cut-off  value.
Retrospective  follow-up  study:  the  purpose  of  the  ret-
rospective  follow-up  study  was  to  analyze  the  usefulness  of
the  EBV  load  variation  as  PTLD  indicator.  The  diagnostic  abil-
ity  of  the  EBV  load  kinetic  variation  for  detecting  total  PTLD
was  evaluated  in  samples  taken  before  and  at  the  moment  of
the  diagnosis  for  PTLD  cases,  and  between  successive  sam-
ples  for  organ  recipients  without  a  PTLD  history.  The  analysis
was  run  on  paired  PBMC  and  plasma  samples.
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Figure  1  EBV  load  in  the  transplanted  population.  (A)  EBV  load  
plasma; (C)  EBV  load  in  oropharyngeal  lymphoid  tissue  cells,  OLT.113
tatistical  analysis
ensitivity,  speciﬁcity,  positive  and  negative  predictive  val-
es  were  calculated  applying  the  Describe  program,  version
.41,  from  the  software  package  WinPEPI,  version  11.14.
esults
he  EBV  load  measured  in  PBMC,  plasma  and  OLT  samples
rom  transplant  patients  with  and  without  PTLD  diagnosis  is
hown  in  Figure  1A--C,  respectively.
linical  validation
ransversal  design
eripheral  blood  mononuclear  cells.  The  analysis  of  the
bility  of  PBMC-measured  EBV  load  to  identify  PTLD  is  shown
n  Fig.  2.  The  highest  diagnostic  efﬁcacy  for  the  detection
f  total  PTLD  is  achieved  at  a  cut-off  value  of  1.08  log  gEq
er  105 PBMC  (A);  for  advanced  PTLD,  at  a  cut-off  of  1.60  log
Eq  per  105 PBMC  (B),  and  for  neoplastic  PTLD,  at  a  cut-off
f  2.47  log  gEq  per  105 PBMC  (C).
lasma.  Fig.  3  describes  the  sensitivity  and  speciﬁcity  of
BV  levels  in  plasma  samples  for  PTLD  diagnosis.  The  EBV
oad  in  plasma  samples  showed  low  sensitivity  and  high
peciﬁcity  to  detect  total  PTLD  (Fig.  3A).  While  increased
ensitivity,  maintaining  high  speciﬁcity,  was  observed  for
he  detection  of  advanced  PTLD  (Fig.  3B),  similar  results
ere  obtained  when  analyzing  only  neoplastic  PTLD  (data
ot  shown).
ymphoid  tissue.  The  best  relations  between  sensitiv-
ty  (Se)  and  speciﬁcity  (Sp)  for  the  detection  of  total,
dvanced  or  neoplastic  PTLD  were  obtained  at  cut-off  val-
es  of  2.30  log  (Se  =  57.4  %  and  Sp  =  55.5  %),  2.60  log  (Se  =
3.6  %  and  Sp  =  66.7  %)  or  4.48  log  gEq  per  105 cells  (Se  =  100  %
nd  Sp  =  100  %),  respectively  (data  not  shown).
ombination  of  several  samples.  In  order  to  improve  the
iagnostic  performance  for  PTLD  detection,  the  combination
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Figure  2  Analysis  of  the  EBV  load  from  PBMC  samples.  The  best  diagnostic  performance  of  the  PBMC  EBV  load  to  detect  different
PTLD categories  required  increasing  cut-off  values.  (A)  Total  PTLD:  included  categories  1--4;  (B)  advanced  PTLD:  categories  2--4;
(C) neoplastic  PTLD:  categories  3  and  4.
Table  2  Diagnostic  performance  of  the  EBV  load  measured  on  several  sample  types  for  PTLD  detection
Cut-off  value  Sensitivitya Speciﬁcityb PPVc NPVd
≥Log  1.08  gEq/105 PBMC  +  ≥Log  2.00/ml  plasma 87.5 60.5 70.0 60.5
≥Log  1.08  gEq/105 PBMC  +  ≥Log  2.30  gEq/105 OLTe cells 67.3 52.6 80.4  35.7
≥Log 1.08  gEq/105 PBMC  +  ≥Log  2.00  gEq/ml
plasma  +  ≥Log  2.30  gEq/105 OLTe cells
72.2 47.4 79.6 34.6
gEq: EBV genome equivalents.
a Sensitivity = [Number of true positives/(Number of true positives + Number of false negatives)] × 100.
b Speciﬁcity = [Number of true negatives/(Number of true negatives + Number of false positives)] × 100.
c Positive predictive value = [Number of true positives/(Number of true positives + Number of false positives)] × 100.
d Negative predictive value = [Number of true negatives/(Number of true negatives + Number of false negatives)] × 100.
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2For calculations, the histological diagnosis was considered the go
e OLT: oropharyngeal lymphoid tissue.
f  the  EBV  load  measured  in  different  anatomical  sites  of
iral  persistence  was  analyzed  (Table  2).  The  most  effective
otal  PTLD  detection  was  obtained  by  co-measuring  the  EBV
oad  in  PBMC  and  plasma.  However,  the  incorporation  of  the
LT  viral  load  did  not  improve  diagnostic  eﬁccacy.
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esults  from  the  retrospective  follow-up  study  are  shown  in
igure  4  and  Tables  3  and  4.  The  determination  of  the  kinetic
oad  variation  increased  diagnostic  efﬁcacy  compared  to
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Figure  4  Kinetics  of  EBV  load  in  PBMC  and  plasma  from  transplant  patients.  Recipients  with  PTLD  history:  (A--F)  Patients  without
PTLD history:  (G--L)  FLH:  follicular  lymphoid  hyperplasia.  PH:  plasmacytic  hyperplasia.  HL:  Hodgkin  lymphoma.  DLCBL:  Diffuse  large
nucle
)  EB
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w
i
nB cell  lymphoma.  IS:  immunosuppression.  IM:  infectious  mono
detection of  primary  EBV  infection.  ()  EBV  load  from  PBMC;  (
co-measurement  of  the  kinetic  variation  in  more  than  one
clinical  sample  improved  the  diagnostic  ability  of  the  assay.
DiscussionMany  of  the  publications  in  which  EBV  load  was  used  to  iden-
tify  PTLD  were  based  on  patients  diagnosed  with  neoplastic
categories14,15.  This  would  explain  the  high  threshold  levels
applied  by  different  laboratories,  which  could  be  considered
I
o
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t
Table  3  Description  of  the  kinetic  variation  of  EBV  load  in  PBMC  
Patients  Histological
diagnosis
A  PH
HL
B  DLCBL  
C DLCBL  
D PH  
E DLCBL  
F PH  
PH: plasmacytic hyperplasia (Category 1 of PTLD); HL: Hodgkin lympho
(Category 3 of PTLD).
NA: Not applicable because EBV load remained not detectable.
a Positive kinetic variation: ≥0.5 log rise in EBV load; Negative kinetic
in EBV load.
b Although EBV load did not show a positive kinetic variation, when
detected at the moment of PH identiﬁcation.osis.  KS:  Kaposi’s  sarcoma.  Tx:  time  of  transplantation.  EBV:
V  load  from  plasma;  x  axis:  sampling  times.
onsistent  with  those  proposed  in  the  present  study  for  iden-
ifying  neoplastic  lymphoproliferations  (transversal  study).
hus,  considering  the  present  data,  the  highest  EBV  levels
ould  be  particularly  associated  with  neoplasia.  The  def-
nition  of  high  load  based  on  a  cut-off  value  that  detects
eoplastic  cases  may  not  be  useful  for  prevention  purposes.
n  such  sense,  few  reports  exist  that  describe  the  amount
f  EBV  associated  with  the  different  categories  of  PTLD21.
ccording  to  the  present  results,  early  PTLD  stages  tend
o  show  a  number  of  EBV  genomes  in  all  anatomical  sites
and  plasma  from  transplant  patients  at  PTLD  diagnosis
Kinetic  load
variationa PBMC
(log  differences)
Kinetic  load
variationa Plasma
(log  differences)
Negative  (−1.34)
Positive  (0.70)
Positive  (1.73)
Negative  (0.30)b
Negative  (0.37)  Positive  (1.16)
Positive  (0.55)  Positive  (2.47)
Positive  (0.56)  Positive  (0.98)
Positive  (0.83)  Negative  (0.15)
Positive  (0.77)  NA
ma (Category 4 of PTLD); DLCBL: Diffuse large B cell lymphoma
 variation: <0.5 log rise or a decrease (indicated by a minus sign)
 HL was diagnosed it remained in high levels, similar to those
116  M.D.  Fellner  et  al.
Table  4  Description  of  the  kinetic  variation  of  EBV  load  in  PBMC  and  plasma  from  transplant  patients  without  a  PTLD  diagnosis
Patients  Histological
diagnosis
Kinetic  load  variationa
PBMC  (log  differences)
Kinetic  load  variationa
Plasma  (log  differences)
G  FLH  Negative  (−0.96)
Positive  (1.46)
Negative  (−0.74)
Positive  (0.64)
Negative  (−0.03)
Negative  (−0.93)
NA
NA
NA
NA
NA
NA
H FLH  Negative  (−0.97)
Positive  (2.45)
Negative  (−1.33)
Negative  (−0.60)
NA
NA
NA
NA
I FLH  Positive  (0.54)
Negative  (−0.11)
Positive  (1.48)
Negative  (−0.34)
Positive  (0.63)
Negative  (−0.63)
NA
NA
J FLH  Negative  (−1.24)
Negative  (−1.73)
Positive  (2.78)
Negative  (−0.95)
Positive  (0.13)
Negative  (−2.13)
NA
NA
NA
Negative  (0.12)
K FLH  Negative  (−1.39)
Positive  (0.74)
Negative  (0.31)
Negative  (−0.62)
Negative  (−0.61)
Negative  (0.37)
Negative  (−0.37)
NA
NA
NA
L FLH  Negative  (0.12)
Negative  (−0.97)
Negative  (0.40)
Negative  (0.04)
Negative  (−0.37)
Positive  (1.10)
Negative  (−1.10)
NA
FLH: follicular lymphoid hyperplasia.
NA: Not applicable because viral load remained not detectable.
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tPositive kinetic variation: ≥0.5 log rise in EBV load. Negative k
in EBV load.
f  viral  persistence,  lower  than  that  observed  in  neoplastic
ategories  (transversal  study).
Therefore,  considering  that  the  aim  of  the  EBV  quan-
iﬁcation  in  transplant  patients  is  to  detect  the  onset  of
ymphoproliferation,  we  wondered  which  monitoring  strat-
gy  would  be  the  best.  Thus,  a  cut-off  of  2.48  log  gEq  per
05 PBMC  would  point  to  neoplastic  PTLD  patients,  but  many
ases  with  less  advanced  stages  would  be  missed.  A  cut-off
alue  of  1.08  log  gEq  per  105 PBMC  would  detect  the  major-
ty  of  organ  recipients  with  PTLD,  but  would  also  include
any  without  PTLD.
Table  5  Diagnostic  performance  of  the  kinetic  variation  of
EBV load  for  PTLD  detection
Kinetic  load
variation
Sensitivity  Speciﬁcity  PPVa NPVb
PBMC  83.3  57.7  31.3  93.7
Plasma  80  80.8  44.4  95.5
PBMC +  Plasma  83.3  81.8  55.6  94.7
a Positive predictive value.
b Negative predictive value.
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b variation: <0.5 log rise or a decrease (indicated by a minus sign)
It  has  already  been  proposed  that  a  high  EBV  load  in
lasma  is  a  more  speciﬁc  PTLD  marker  than  its  determina-
ion  in  PBMC23;  however,  it  is  also  less  sensitive1. According
o  the  present  transversal  study,  the  detection  of  EBV  DNA
n  plasma  samples  appears  to  be  a  sensitive  and  speciﬁc
ndicator  of  advanced  PTLD,  albeit  very  insensitive  to  iden-
ify  early  phases.  In  addition,  as  noted  in  the  retrospective
ollow-up  (Fig.  4),  two  patients  showed  undetectable  EBV
oad  in  plasma  at  PTLD  diagnosis,  one  in  category  1  (case  F)
nd  one  even  in  a  neoplastic  stage  (case  E).
The  levels  of  EBV  in  lymphoid  tissue  are  not  usually  ana-
yzed  to  detect  PTLD  since  peripheral  blood  samples  are
ess  invasive  and  more  easily  available.  In this  respect,  the
resent  data  showed  that  a  high  amount  of  EBV  DNA  in  lym-
hoid  tissue  exhibits  the  highest  ability  for  neoplastic  PTLD
etection,  but  not  for  less  advanced  categories.
In  most  reports,  the  determination  of  an  increased
BV  load  in  a  single  blood  sample  type  is  used  for  PTLD
dentiﬁcation1; however  it  has  also  been  suggested  that  the
imultaneous  evaluation  of  whole  blood  and  plasma  sam-
les  allows  for  better  diagnosis  and  monitoring,  and  may  be
sed  to  rule  out  their  presence23. Thus,  among  all  the  com-
inations  analyzed  in  the  present  report,  the  simultaneous
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REBV  load  and  early  detection  of  PTLD  
measurement  of  EBV  load  in  PBMC  and  plasma  resulted  in  a
greater  diagnostic  efﬁcacy  regarding  the  quantiﬁcation  of  a
single  sample  type  (transversal  study).
Moreover,  as  the  retrospective  follow-up  showed  the
kinetic  variation  of  the  EBV  levels  measured  in  PBMC  or
plasma,  it  evidenced  a  better  diagnostic  ability  than  the
use  of  a  single  cut-off  value;  these  results  are  consistent
with  already  reported  data6.  Furthermore,  an  increased  risk
of  PTLD  was  demonstrated  when  detecting  viral  level  varia-
tions  in  patients  with  persistent  high  EBV  loads2.
Therefore,  it  has  been  concluded  that  the  best  strategy  to
monitor  transplant  patients,  regarding  the  detection  of  the
early  stages  of  PTLD  and  the  risk  of  progressing  to  neoplastic
categories  would  include  the  following  algorithm.  Initially,
it  includes  the  monitoring  of  the  EBV  load  in  PBMC,  taking
into  account  that:
(1)  An  EBV  load  below  1.08  log  gEq  per  105 PBMC  implies
low  risk.  Thus,  the  patient’s  routine  monitoring  should
be  continued.
(2)  An  EBV  load  between  1.08  log  and  2.48  log  gEq  per  105
PBMC  involves  an  increased  risk.  A  more  frequent  mon-
itoring  of  the  EBV  load  in  PBMC  is  required  to  detect
a  kinetic  variation,  plus  the  monitoring  of  viral  levels
in  plasma.  The  detection  of  a  kinetic  variation  in  PBMC
and/or  an  EBV  load  in  plasma  greater  than  2  log  gEq/ml
involves  high  PTLD  risk.
(3)  An  EBV  load  above  2.48  log  gEq  per  105 PBMC  plus  the
detection  of  viral  levels  greater  than  2.52  log  gEq/ml  in
plasma  imply  a  high  risk  of  neoplastic  PTLD.  The  greater
the  EBV  load  and/or  the  simultaneous  detection  of  a
kinetic  variation,  the  greater  the  risk  of  neoplastic  PTLD
stages.
It  should  be  borne  in  mind  that  the  algorithm  requires
some  consideration.  Firstly,  the  overlap  in  the  EBV  DNA
levels  in  PBMC  among  transplant  patients  with  and  with-
out  PTLD.  It  should  be  noted  that  according  to  the  present
results  and  coinciding  with  other  authors14,  not  all  EBV  loads
deﬁned  as  ‘‘high’’  imply  the  development  of  PTLD.
Carefully  monitoring  an  organ  recipient  with  a  low  or
moderate  EBV  load  is  also  suggested,  since  a  small  increase
in  viral  levels  may  be  associated  with  PTLD,  as  was  observed
in  this  study  and  previously  reported  ones16.
The  suggested  algorithm  aims  to  identify  PTLD  in  the  most
effective  way;  however  there  are  patients  with  PTLD  that
remain  undetected  and  recipients  without  PTLD  who  are
included  as  risky.  This  points  to  the  need  for  more  speciﬁc
markers  that,  when  combined  with  the  viral  load,  result  in  a
more  accurate  selection  of  cases  of  incipient  PTLD,  allowing
to  reverse  lymphoproliferation  in  its  initial  stages.
It  should  be  mentioned  that  the  study  presented  some
limitations.  One  of  them  is  the  variety  of  transplanted  organs
included,  as  they  show  different  PTLD  prevalence.  However,
as  the  EBV  levels  in  healthy  carriers  were  known5,  the  ini-
tial  point  of  rising  load  (shared  by  all  the  transplanted  organ
groups)  could  be  identiﬁed.  Furthermore,  the  number  of
patients  included  into  each  PTLD  category  was  quite  differ-
ent,  being  the  initial  stages  of  PTLD  (category  1)  the  broader.
Such  category  1  just  depicted  the  beginning  of  the  lym-
phoproliferation  process,  which  was  the  aim  of  the  present117
tudy;  however,  all  stages  of  the  process  were  analyzed  sep-
rately  in  order  to  describe  the  differences  among  them.
Finally,  considering  that  the  determination  of  the  EBV
oad  lacks  a  gold  standard  strategy  worldwide,  this  paper
rovides  an  in-house  methodology,  which  is  analytical,  clin-
cally  validated,  less  expensive  and  more  accessible  than
ommercial  assays.  Thus,  it  may  represent  an  initial,  but
ery  helpful  step  for  the  monitoring  of  transplant  patients,
specially  in  low  resource  settings,  where  commercial  kits
re  not  affordable.
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